Bahaa Sharafeldeen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Bahaa Sharafeldeen has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Alaa M. Wafa
Diabetes and Endocrinology Unit, Department of Internal Medicine, Faculty of Medicine, Mansoura University, Mansoura 35516, Egypt
1 shared publication - Azza A. Ismail
Unit of Diabetes, Lipidology and Metabolism, Department of Internal Medicine, Faculty of Medicine, Alexandria University, Alexandria 21526, Egypt
1 shared publication - Magdy Helmy Megallaa
Unit of Diabetes, Lipidology and Metabolism, Department of Internal Medicine, Faculty of Medicine, Alexandria University, Alexandria 21526, Egypt
1 shared publication - Mary N. Rizk
Department of Internal Medicine, Faculty of Medicine, Cairo University, Giza 12613, Egypt
1 shared publication - Mohamed A. Korani
Unit of Diabetes, Lipidology and Metabolism, Department of Internal Medicine, Faculty of Medicine, Alexandria University, Alexandria 21526, Egypt
1 shared publication - Noha Gaber Amin
Professor of Internal Medicine, Diabetes and Metabolism Unit, Faculty of Medicine, Alexandria University
1 shared publication
Latest Publications
- Open Access
- 6 May 2026
- Published by MDPI AG in Diabetology
- Vol. 7 (5) , 90
Simplifying Treatment for Type 2 Diabetes: Egyptian Consensus Recommendations on Fixed-Ratio Combinations
Background/Objectives: Egypt ranks among the top ten countries globally with the highest burden of type 2 diabetes mellitus (T2DM), with prevalence projected to rise significantly by 2050. Despite multiple therapeutic options, glycemic control remains suboptimal due to therapeutic inertia, treatment complexity, and healthcare system limitations. Fixed-ratio combinations (FRCs) of basal insulin and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) offer a simplified injectable strategy addressing complementary pathophysiological defects in T2DM. This study aims to develop expert consensus recommendations for the use of FRCs in Egyptian adults with T2DM, integrating international evidence with local practice. Methods: A modified Delphi technique was employed to achieve consensus among 9 diabetes experts across Egypt. Statements were formulated based on a targeted literature review and voted on using a structured Likert scale. Consensus was defined as ≥70% agreement. Results: Twenty-nine statements were endorsed with strong to very strong consensus. Recommendations covered patient selection, initiation after oral therapy or GLP-1 RA, switching from premixed or complex insulin regimens, dosing strategies, safety considerations, and intensification options. FRCs were favored for early injectable use, regimen simplification, and improved adherence, with liraglutide-based FRCs preferred for cardiovascular and renal benefits. Digital health integration was strongly recommended to enhance glycemic control and patient engagement. Conclusions: FRCs offer a simple and effective treatment simplification option for patients with uncontrolled T2DM on premix insulin, complex insulin regimens, or oral therapy. FRCs may improve glycemic control with generally favorable effects on hypoglycemia risk and body weight across many randomized and real-world studies, while reducing injection burden, simplifying the treatment regimen, and supporting patient adherence and satisfaction.
- 6 May 2026
- Published by MDPI AG in Diabetology
- Vol. 7 (5) , 90
Open AccessSimplifying Treatment for Type 2 Diabetes: Egyptian Consensus Recommendations on Fixed-Ratio Combinations
Background/Objectives: Egypt ranks among the top ten countries globally with the highest burden of type 2 diabetes mellitus (T2DM), with prevalence projected to rise significantly by 2050. Despite multiple therapeutic options, glycemic control remains suboptimal due to therapeutic inertia, treatment complexity, and healthcare system limitations. Fixed-ratio combinations (FRCs) of basal insulin and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) offer a simplified injectable strategy addressing complementary pathophysiological defects in T2DM. This study aims to develop expert consensus recommendations for the use of FRCs in Egyptian adults with T2DM, integrating international evidence with local practice. Methods: A modified Delphi technique was employed to achieve consensus among 9 diabetes experts across Egypt. Statements were formulated based on a targeted literature review and voted on using a structured Likert scale. Consensus was defined as ≥70% agreement. Results: Twenty-nine statements were endorsed with strong to very strong consensus. Recommendations covered patient selection, initiation after oral therapy or GLP-1 RA, switching from premixed or complex insulin regimens, dosing strategies, safety considerations, and intensification options. FRCs were favored for early injectable use, regimen simplification, and improved adherence, with liraglutide-based FRCs preferred for cardiovascular and renal benefits. Digital health integration was strongly recommended to enhance glycemic control and patient engagement. Conclusions: FRCs offer a simple and effective treatment simplification option for patients with uncontrolled T2DM on premix insulin, complex insulin regimens, or oral therapy. FRCs may improve glycemic control with generally favorable effects on hypoglycemia risk and body weight across many randomized and real-world studies, while reducing injection burden, simplifying the treatment regimen, and supporting patient adherence and satisfaction.